Avalyn Pharma develops improved therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Location: United States, Washington, Seattle
Total raised: $210.5M
Investors 8
Funding Rounds 2
| Date | Series | Amount | Investors |
| 05.10.2023 | Series C | $175M | - |
| 28.04.2020 | Series B | $35.5M | - |
Mentions in press and media 13
| Date | Title | Description |
| 22.07.2025 | Avalyn raises $100M to advance inhaled versions of approved lung disease meds | Avalyn Pharma has added on $100 million to accelerate novel inhaled versions of approved drugs for lung conditions. The company’s series D fundraise was led by Suvretta Capital Management and SR One and included 16 other investors, such as ... |
| 16.11.2023 | No new unicorns in Seattle: The billion-dollar startup milestone is harder to reach these days | (GeekWire Photo Illustration / Photo by Kevin Lisota) The unicorn stampede in Seattle has screeched to a halt. During venture capital boom times in the midst of the pandemic, Seattle birthed a number of “unicorns,” a term defined a decade a... |
| 05.10.2023 | Avalyn: Targeted Inhalation Therapy Company Raises $175 Million | Avalyn Pharma – a clinical-stage biopharmaceutical company focused on developing targeted inhalation therapies for life-threatening pulmonary diseases – announced the closing of an oversubscribed $175 million Series C financing. Avalyn plan... |
| 03.10.2023 | VC funding to Pacific Northwest startups in Q3 was down nearly 50% year-over-year | Seattle’s skyline with Mount Rainier in the background. (GeekWire Photo / Nate Bek) Pacific Northwest startups raised $920 million in the third quarter, marking the lowest quarterly amount in five years and a 46% drop compared to the same t... |
| 29.09.2023 | Avalyn Raises $175 Million in Series C Financing | SEATTLE, WA, Avalyn Pharma Inc., a clinical-stage biopharmaceutical company, announced the closing of an oversubscribed $175 million Series C financing. >> Click here for more funding data on Avalyn Pharma >> To export Avaly... |
| 27.09.2023 | Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies | - |
| 27.09.2023 | Avalyn Pharma Closes $175M Series C Financing | Avalyn Pharma Inc., a Seattle, WA-based clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary diseases, closed a $175m Series C financing. The round was co-led by Per... |
| 27.09.2023 | Avalyn raises $175M to test inhaler versions of IPF medicines in PhII trials | - |
| 27.09.2023 | Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies | - |
| 28.04.2020 | Avalyn Pharma Secures $35.5M Series B | SEATTLE, WA, Avalyn Pharma announced the completion of a $35.5 million Series B financing. >> Click here for more funding data on Avalyn Pharma >> To export Avalyn Pharma funding data to PDF and Excel, click here Avalyn P... |
Show more